why choose us

300×250 Ad Slot

Research Article: Radiation and systemic immunotherapy for metastatic uveal melanoma: a clinical retrospective review

Date Published: 2024-07-04

Abstract:
Introduction: Metastatic uveal melanoma (mUM) is a difficult to treat disease. The liver is the primary site of metastasis in most patients, though uveal melanoma spreads widely in advanced disease. The only FDA approved immunotherapy medication for metastatic uveal melanoma is the HLA-A02:01 restricted bispecific T cell engager drug, Tebentafusp. Checkpoint inhibitor strategies and combination approaches have been tried with some limited success. We describe our experience treating patients at the University of Minnesota.

No summary available.

300×250 Ad Slot